These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37555281)

  • 1. Cost-effectiveness analysis of pediatric immunization program with 15-valent pneumococcal conjugate vaccine in Japan.
    Tajima A; Abe M; Weaver J; Huang M
    J Med Econ; 2023; 26(1):1034-1046. PubMed ID: 37555281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina.
    Rey-Ares L; Ta A; Freigofaite D; Warren S; Mac Mullen M; Carballo C; Huang L
    Vaccine; 2024 Oct; 42(23):126043. PubMed ID: 38879409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan.
    Shinjoh M; Togo K; Hayamizu T; Yonemoto N; Morii J; Perdrizet J; Kamei K
    Expert Rev Vaccines; 2024; 23(1):485-497. PubMed ID: 38682661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis.
    Ta A; Kühne F; Laurenz M; von Eiff C; Warren S; Perdrizet J
    Infect Dis Ther; 2024 Jun; 13(6):1333-1358. PubMed ID: 38733494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in children in the United States.
    Hu T; Weiss T; Owusu-Edusei K; Petigara T
    J Med Econ; 2020 Dec; 23(12):1653-1660. PubMed ID: 33084447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health and economic burden of invasive pneumococcal disease associated with 15-valent pneumococcal conjugate vaccine serotypes in children across eight European countries.
    Hu T; Weiss T; Bencina G; Owusu-Edusei K; Petigara T
    J Med Econ; 2021; 24(1):1098-1107. PubMed ID: 34461796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness Analysis of Routine Use of 15-Valent Pneumococcal Conjugate Vaccine in the US Pediatric Population.
    Huang M; Hu T; Weaver J; Owusu-Edusei K; Elbasha E
    Vaccines (Basel); 2023 Jan; 11(1):. PubMed ID: 36679980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.
    Delgleize E; Leeuwenkamp O; Theodorou E; Van de Velde N
    BMJ Open; 2016 Nov; 6(11):e010776. PubMed ID: 27903558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.
    Shen K; Wasserman M; Liu D; Yang YH; Yang J; Guzauskas GF; Wang BCM; Hilton B; Farkouh R
    PLoS One; 2018; 13(7):e0201245. PubMed ID: 30044865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong.
    Wu DB; Roberts C; Lee VW; Hong LW; Tan KK; Mak V; Lee KK
    Hum Vaccin Immunother; 2016; 12(2):403-16. PubMed ID: 26451658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population.
    Fridh AC; Palmborg A; Ta A; Freigofaite D; Warren S; Perdrizet J
    Hum Vaccin Immunother; 2024 Dec; 20(1):2400751. PubMed ID: 39279284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia.
    Sundaram N; Chen C; Yoong J; Luvsan ME; Fox K; Sarankhuu A; La Vincente S; Jit M
    Vaccine; 2017 Feb; 35(7):1055-1063. PubMed ID: 28109706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of the 15-valent pneumococcal conjugate vaccine for high-risk adults in Switzerland.
    Deb A; Guggisberg P; Mutschler T; Owusu-Edusei K; Bencina G; Johnson KD; Ignacio T; Mathijssen DAR; Qendri V
    Expert Rev Vaccines; 2022 May; 21(5):711-722. PubMed ID: 35220875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population.
    Lytle D; Grajales Beltrán AG; Perdrizet J; Ait Yahia N; Cane A; Yarnoff B; Chapman R
    Hum Vaccin Immunother; 2023 Aug; 19(2):2257426. PubMed ID: 37771288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia.
    Lagoubi Y; Sfar MT; Gomez JA
    Hum Vaccin Immunother; 2022 Nov; 18(5):2079305. PubMed ID: 35703731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Comparison of Pneumococcal Conjugate Vaccines in Turkish Children.
    Marijam A; Olbrecht J; Ozakay A; Eken V; Meszaros K
    Value Health Reg Issues; 2019 Sep; 19():34-44. PubMed ID: 30776766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland.
    Owusu-Edusei K; Favre-Bulle A; Tsoumani E; Mutschler T; Cossrow N
    Vaccine; 2024 May; 42(13):3239-3246. PubMed ID: 38609806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.
    Kuhlmann A; von der Schulenburg JG
    Eur J Health Econ; 2017 Apr; 18(3):273-292. PubMed ID: 26905404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants.
    Rozenbaum MH; Huang L; Perdrizet J; Cane A; Arguedas A; Hayford K; Tort MJ; Chapman R; Dillon-Murphy D; Snow V; Chilson E; Farkouh RA
    Vaccine; 2024 Jan; 42(3):573-582. PubMed ID: 38191278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.